Summary
Global Markets Direct’s, ‘Bladder Cancer - Pipeline Review, H1 2016’, provides an overview of the Bladder Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews pipeline therapeutics for Bladder Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bladder Cancer therapeutics and enlists all their major and minor projects
- The report assesses Bladder Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bladder Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
ADC Therapeutics Sarl
Advaxis, Inc.
Agenus, Inc.
Alligator Bioscience AB
Alnylam Pharmaceuticals, Inc.
Altor BioScience Corporation
AndroScience Corporation
APIM Therapeutics AS
Arno Therapeutics, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Azaya Therapeutics, Inc.
Bavarian Nordic A/S
Bayer AG
BioCancell Ltd
Biomics Biotechnologies Co., Ltd.
Bioncotech Therapeutics S.L.
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cold Genesys, Inc.
Corvus Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
DormaTarg, Inc.
Eisai Co., Ltd.
enGene, Inc
Esperance Pharmaceuticals, Inc.
Evotec AG
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Gene Signal International SA
Genmab A/S
GlaxoSmithKline Plc
Heat Biologics, Inc.
HEC Pharm Co., Ltd.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
ImmuNext, Inc.
Immunomedics, Inc.
Immupharma Plc
LipoMedix Pharmaceutical Inc.
MacroGenics, Inc.
Meabco A/S
Medicenna Therapeutics, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Mirati Therapeutics Inc.
NanoCarrier Co., Ltd.
NuCana BioMed Limited
Omeros Corporation
Oncogenex Pharmaceuticals, Inc.
Oncolytics Biotech Inc.
Ono Pharmaceutical Co., Ltd.
Optimum Therapeutics, LLC
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Qu Biologics Inc.
Rexahn Pharmaceuticals, Inc.
Rodos BioTarget GmbH
Samyang Holdings Corporation
Sanofi
Savoy Pharmaceuticals, Inc.
Serometrix, LLC
Shionogi & Co., Ltd.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Sun Pharma Advanced Research Company Ltd.
Synovo GmbH
Synta Pharmaceuticals Corp.
Taiwan Liposome Company, Ltd.
Taris Biomedical LLC
Telesta Therapeutics Inc.
Telormedix SA
Theravectys SA
Theryte Limited
Tolero Pharmaceuticals, Inc.
Transgene SA
UroGen Pharmaceuticals, Ltd.
Vakzine Projekt Management GmbH
Vault Pharma Inc.
Vaxeal Holding SA
Viralytics Ltd.
Viventia Bio Inc.
'
Table of Contents
Table of Contents 2
Introduction 7
Bladder Cancer Overview 8
Therapeutics Development 9
Bladder Cancer - Therapeutics under Development by Companies 11
Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 20
Bladder Cancer - Pipeline Products Glance 21
Bladder Cancer - Products under Development by Companies 24
Bladder Cancer - Products under Investigation by Universities/Institutes 33
Bladder Cancer - Companies Involved in Therapeutics Development 34
Bladder Cancer - Therapeutics Assessment 128
Drug Profiles 148
Bladder Cancer - Recent Pipeline Updates 433
Bladder Cancer - Dormant Projects 647
Bladder Cancer - Discontinued Products 655
Bladder Cancer - Product Development Milestones 656
Appendix 661
List of Tables
Number of Products under Development for Bladder Cancer, H1 2016 26
Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2016 27
Number of Products under Development by Companies, H1 2016 29
Number of Products under Development by Companies, H1 2016 (Contd..1) 30
Number of Products under Development by Companies, H1 2016 (Contd..2) 31
Number of Products under Development by Companies, H1 2016 (Contd..3) 32
Number of Products under Development by Companies, H1 2016 (Contd..4) 33
Number of Products under Development by Companies, H1 2016 (Contd..5) 34
Number of Products under Development by Companies, H1 2016 (Contd..6) 35
Number of Products under Development by Companies, H1 2016 (Contd..7) 36
Number of Products under Investigation by Universities/Institutes, H1 2016 37
Comparative Analysis by Late Stage Development, H1 2016 38
Comparative Analysis by Clinical Stage Development, H1 2016 39
Comparative Analysis by Early Stage Development, H1 2016 40
Products under Development by Companies, H1 2016 41
Products under Development by Companies, H1 2016 (Contd..1) 42
Products under Development by Companies, H1 2016 (Contd..2) 43
Products under Development by Companies, H1 2016 (Contd..3) 44
Products under Development by Companies, H1 2016 (Contd..4) 45
Products under Development by Companies, H1 2016 (Contd..5) 46
Products under Development by Companies, H1 2016 (Contd..6) 47
Products under Development by Companies, H1 2016 (Contd..7) 48
Products under Development by Companies, H1 2016 (Contd..8) 49
Products under Investigation by Universities/Institutes, H1 2016 50
Bladder Cancer - Pipeline by 4SC AG, H1 2016 51
Bladder Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016 52
Bladder Cancer - Pipeline by Advaxis, Inc., H1 2016 53
Bladder Cancer - Pipeline by Agenus, Inc., H1 2016 54
Bladder Cancer - Pipeline by Alligator Bioscience AB, H1 2016 55
Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 56
Bladder Cancer - Pipeline by Altor BioScience Corporation, H1 2016 57
Bladder Cancer - Pipeline by AndroScience Corporation, H1 2016 58
Bladder Cancer - Pipeline by APIM Therapeutics AS, H1 2016 59
Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016 60
Bladder Cancer - Pipeline by Astellas Pharma Inc., H1 2016 61
Bladder Cancer - Pipeline by AstraZeneca Plc, H1 2016 62
Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 63
Bladder Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016 64
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H1 2016 65
Bladder Cancer - Pipeline by Bayer AG, H1 2016 66
Bladder Cancer - Pipeline by BioCancell Ltd, H1 2016 67
Bladder Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016 68
Bladder Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2016 69
Bladder Cancer - Pipeline by Biotest AG, H1 2016 70
Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 71
Bladder Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 72
Bladder Cancer - Pipeline by Celgene Corporation, H1 2016 73
Bladder Cancer - Pipeline by Cellceutix Corporation, H1 2016 74
Bladder Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 75
Bladder Cancer - Pipeline by Cold Genesys, Inc., H1 2016 76
Bladder Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016 77
Bladder Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 78
Bladder Cancer - Pipeline by DormaTarg, Inc., H1 2016 79
Bladder Cancer - Pipeline by Eisai Co., Ltd., H1 2016 80
Bladder Cancer - Pipeline by enGene, Inc, H1 2016 81
Bladder Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016 82
Bladder Cancer - Pipeline by Evotec AG, H1 2016 83
Bladder Cancer - Pipeline by Exelixis, Inc., H1 2016 84
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 85
Bladder Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2016 86
Bladder Cancer - Pipeline by Gene Signal International SA, H1 2016 87
Bladder Cancer - Pipeline by Genmab A/S, H1 2016 88
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 89
Bladder Cancer - Pipeline by Heat Biologics, Inc., H1 2016 90
Bladder Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016 91
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 92
Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 93
Bladder Cancer - Pipeline by ImmuNext, Inc., H1 2016 94
Bladder Cancer - Pipeline by Immunomedics, Inc., H1 2016 95
Bladder Cancer - Pipeline by Immupharma Plc, H1 2016 96
Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H1 2016 97
Bladder Cancer - Pipeline by MacroGenics, Inc., H1 2016 98
Bladder Cancer - Pipeline by Meabco A/S, H1 2016 99
Bladder Cancer - Pipeline by Medicenna Therapeutics, Inc., H1 2016 100
Bladder Cancer - Pipeline by MedImmune, LLC, H1 2016 101
Bladder Cancer - Pipeline by Merck & Co., Inc., H1 2016 102
Bladder Cancer - Pipeline by Merck KGaA, H1 2016 103
Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H1 2016 104
Bladder Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016 105
Bladder Cancer - Pipeline by NuCana BioMed Limited, H1 2016 106
Bladder Cancer - Pipeline by Omeros Corporation, H1 2016 107
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2016 108
Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 109
Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 110
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H1 2016 111
Bladder Cancer - Pipeline by Pfizer Inc., H1 2016 112
Bladder Cancer - Pipeline by Pharma Mar, S.A., H1 2016 113
Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 114
Bladder Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 115
Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016 116
Bladder Cancer - Pipeline by Qu Biologics Inc., H1 2016 117
Bladder Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 118
Bladder Cancer - Pipeline by Rodos BioTarget GmbH, H1 2016 119
Bladder Cancer - Pipeline by Samyang Holdings Corporation, H1 2016 120
Bladder Cancer - Pipeline by Sanofi, H1 2016 121
Bladder Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 122
Bladder Cancer - Pipeline by Serometrix, LLC, H1 2016 123
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H1 2016 124
Bladder Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016 125
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 126
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2016 127
Bladder Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 128
Bladder Cancer - Pipeline by Synovo GmbH, H1 2016 129
Bladder Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 130
Bladder Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 131
Bladder Cancer - Pipeline by Taris Biomedical LLC, H1 2016 132
Bladder Cancer - Pipeline by Telesta Therapeutics Inc., H1 2016 133
Bladder Cancer - Pipeline by Telormedix SA, H1 2016 134
Bladder Cancer - Pipeline by Theravectys SA, H1 2016 135
Bladder Cancer - Pipeline by Theryte Limited, H1 2016 136
Bladder Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 137
Bladder Cancer - Pipeline by Transgene SA, H1 2016 138
Bladder Cancer - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016 139
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H1 2016 140
Bladder Cancer - Pipeline by Vault Pharma Inc., H1 2016 141
Bladder Cancer - Pipeline by Vaxeal Holding SA, H1 2016 142
Bladder Cancer - Pipeline by Viralytics Ltd., H1 2016 143
Bladder Cancer - Pipeline by Viventia Bio Inc., H1 2016 144
Assessment by Monotherapy Products, H1 2016 145
Assessment by Combination Products, H1 2016 146
Number of Products by Stage and Target, H1 2016 148
Number of Products by Stage and Mechanism of Action, H1 2016 156
Number of Products by Stage and Route of Administration, H1 2016 162
Number of Products by Stage and Molecule Type, H1 2016 164
Bladder Cancer Therapeutics - Recent Pipeline Updates, H1 2016 450
Bladder Cancer - Dormant Projects, H1 2016 664
Bladder Cancer - Dormant Projects (Contd..1), H1 2016 665
Bladder Cancer - Dormant Projects (Contd..2), H1 2016 666
Bladder Cancer - Dormant Projects (Contd..3), H1 2016 667
Bladder Cancer - Dormant Projects (Contd..4), H1 2016 668
Bladder Cancer - Dormant Projects (Contd..5), H1 2016 669
Bladder Cancer - Dormant Projects (Contd..6), H1 2016 670
Bladder Cancer - Dormant Projects (Contd..7), H1 2016 671
Bladder Cancer - Discontinued Products, H1 2016 672
List of Figures
Number of Products under Development for Bladder Cancer, H1 2016 26
Number of Products under Development for Bladder Cancer - Comparative Analysis, H1 2016 27
Number of Products under Development by Companies, H1 2016 28
Number of Products under Investigation by Universities/Institutes, H1 2016 37
Comparative Analysis by Late Stage Development, H1 2016 38
Comparative Analysis by Clinical Stage Development, H1 2016 39
Comparative Analysis by Early Stage Products, H1 2016 40
Assessment by Monotherapy Products, H1 2016 145
Assessment by Combination Products, H1 2016 146
Number of Products by Top 10 Targets, H1 2016 147
Number of Products by Stage and Top 10 Targets, H1 2016 147
Number of Products by Top 10 Mechanism of Actions, H1 2016 155
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 155
Number of Products by Top 10 Routes of Administration, H1 2016 161
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 161
Number of Products by Top 10 Molecule Types, H1 2016 163
Number of Products by Stage and Top 10 Molecule Types, H1 2016 163
